ALN-APOC3 / Regeneron, Alnylam - LARVOL DELTA

ALN-APOC3 in Adult Participants With Dyslipidemia (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Regeneron Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Dyslipidemia • Metabolic Disorders • APOB

ALN-APOC3 in Adult Participants With Dyslipidemia (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Regeneron Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=136 ➔ 32

Enrollment change • Enrollment closed • Dyslipidemia • Metabolic Disorders • APOB

ALN-APOC3 in Adult Participants With Dyslipidemia (clinicaltrials.gov) - P1 | N=136 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Phase classification: P1/2 ➔ P1 | Trial completion date: Jul 2027 ➔ Feb 2026 | Trial primary completion date: Jul 2027 ➔ Feb 2026

Phase classification • Trial completion date • Trial primary completion date • Dyslipidemia • Metabolic Disorders • APOB

ALN-APOC3 in Adult Participants With Dyslipidemia (clinicaltrials.gov) - P1/2 | N=136 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia • Metabolic Disorders